Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 517

1.

Retrospective single center analysis of outcome, risk factors and therapy in steroid refractory graft-versus-host disease after allogeneic hematopoietic cell transplantation.

Axt L, Naumann A, Toennies J, Haen SP, Vogel W, Schneidawind D, Wirths S, Moehle R, Faul C, Kanz L, Axt S, Bethge WA.

Bone Marrow Transplant. 2019 May 14. doi: 10.1038/s41409-019-0544-y. [Epub ahead of print]

PMID:
31089279
2.

Comparison of Dynamic International Prognostic Scoring System and MYelofibrosis SECondary to PV and ET Prognostic Model for Prediction of Outcome in Polycythemia Vera and Essential Thrombocythemia Myelofibrosis after Allogeneic Stem Cell Transplantation.

Gagelmann N, Eikema DJ, de Wreede LC, Koster L, Wolschke C, Arnold R, Kanz L, McQuaker G, Marchand T, Socié G, Bourhis JH, Mohty M, Cornelissen JJ, Chevallier P, Bernasconi P, Stelljes M, Rohrlich PS, Fanin R, Finke J, Maertens J, Blaise D, Itälä-Remes M, Labussière-Wallet H, Robin M, McLornan D, Chalandon Y, Yakoub-Agha I, Kröger N; CMWP of the European Society for Blood and Marrow Transplantation.

Biol Blood Marrow Transplant. 2019 Jun;25(6):e204-e208. doi: 10.1016/j.bbmt.2019.03.024. Epub 2019 Mar 28.

PMID:
30930192
3.

G-CSF administration prior to donor lymphocyte apheresis promotes anti-leukaemic effects in allogeneic HCT patients.

Schneidawind C, Jahnke S, Schober-Melms I, Schumm M, Handgretinger R, Faul C, Kanz L, Bethge W, Schneidawind D.

Br J Haematol. 2019 Jul;186(1):60-71. doi: 10.1111/bjh.15881. Epub 2019 Mar 27.

PMID:
30916396
4.

Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation.

Gagelmann N, Eikema DJ, Stelljes M, Beelen D, de Wreede L, Mufti G, Knelange NS, Niederwieser D, Friis LS, Ehninger G, Nagler A, Yakoub-Agha I, Meijer E, Ljungman P, Maertens J, Kanz L, Lopez-Corral L, Brecht A, Craddock C, Finke J, Cornelissen JJ, Bernasconi P, Chevallier P, Sierra J, Robin M, Kröger N.

Haematologica. 2019 May;104(5):929-936. doi: 10.3324/haematol.2018.200808. Epub 2019 Jan 17.

5.

Human iPSC-based model of severe congenital neutropenia reveals elevated UPR and DNA damage in CD34+ cells preceding leukemic transformation.

Dannenmann B, Zahabi A, Mir P, Oswald B, Bernhard R, Klimiankou M, Morishima T, Schulze-Osthoff K, Zeidler C, Kanz L, Lachmann N, Moritz T, Welte K, Skokowa J.

Exp Hematol. 2019 Mar;71:51-60. doi: 10.1016/j.exphem.2018.12.006. Epub 2019 Jan 4.

PMID:
30615903
6.

Loss of NFAT2 expression results in the acceleration of clonal evolution in chronic lymphocytic leukemia.

Müller DJ, Wirths S, Fuchs AR, Märklin M, Heitmann JS, Sturm M, Haap M, Kirschniak A, Sasaki Y, Kanz L, Kopp HG, Müller MR.

J Leukoc Biol. 2019 Mar;105(3):531-538. doi: 10.1002/JLB.2AB0218-076RR. Epub 2018 Dec 17.

PMID:
30556925
7.

The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy.

Bilich T, Nelde A, Bichmann L, Roerden M, Salih HR, Kowalewski DJ, Schuster H, Tsou CC, Marcu A, Neidert MC, Lübke M, Rieth J, Schemionek M, Brümmendorf TH, Vucinic V, Niederwieser D, Bauer J, Märklin M, Peper JK, Klein R, Kohlbacher O, Kanz L, Rammensee HG, Stevanović S, Walz JS.

Blood. 2019 Feb 7;133(6):550-565. doi: 10.1182/blood-2018-07-866830. Epub 2018 Dec 10.

PMID:
30530751
8.

Culture-Expanded Human Invariant Natural Killer T Cells Suppress T-Cell Alloreactivity and Eradicate Leukemia.

Schmid H, Schneidawind C, Jahnke S, Kettemann F, Secker KA, Duerr-Stoerzer S, Keppeler H, Kanz L, Savage PB, Schneidawind D.

Front Immunol. 2018 Aug 6;9:1817. doi: 10.3389/fimmu.2018.01817. eCollection 2018.

9.

First case report of malignant peritoneal mesothelioma and oral verrucous carcinoma in a patient with a germline PTEN mutation: a combination of extremely rare diseases with probable further implications.

Löffler MW, Steinhilber J, Hilke FJ, Haen SP, Bösmüller H, Montes-Mojarro IA, Bonzheim I, Stäbler A, Faust U, Grasshoff U, Königsrainer I, Rammensee HG, Kanz L, Königsrainer A, Beckert S, Riess O, Schroeder C.

BMC Med Genet. 2018 Aug 15;19(1):144. doi: 10.1186/s12881-018-0651-4.

10.

Second allogeneic hematopoietic cell transplantation enables long-term disease-free survival in relapsed acute leukemia.

Schneidawind C, Hagmaier V, Faul C, Kanz L, Bethge W, Schneidawind D.

Ann Hematol. 2018 Dec;97(12):2491-2500. doi: 10.1007/s00277-018-3454-y. Epub 2018 Jul 31.

PMID:
30066039
11.

Long-term remission of refractory Rosai-Dorfman disease after salvage therapy with clofarabine in an adult patient.

Hinterleitner C, Steurer M, Dörfel D, Heitmann J, Kreisselmeier KP, Müller K, Kopp HG, Wirths S, Haap M, de Fend LQ, Horger M, Rodriguez-Galindo C, Kanz L, Müller MR.

Ann Hematol. 2019 Jan;98(1):227-230. doi: 10.1007/s00277-018-3421-7. Epub 2018 Jul 6. No abstract available.

PMID:
29980874
12.

Impact of surgery in patients with metastatic soft tissue sarcoma: A monocentric retrospective analysis.

Wigge S, Heißner K, Steger V, Ladurner R, Traub F, Sipos B, Bösmüller H, Kanz L, Mayer F, Kopp HG.

J Surg Oncol. 2018 Jul;118(1):167-176. doi: 10.1002/jso.25115. Epub 2018 Jun 28.

PMID:
29953623
13.

Paradigm Shift in the Management of Irresectable Colorectal Liver Metastases: Living Donor Auxiliary Partial Orthotopic Liver Transplantation in Combination With Two-stage Hepatectomy (LD-RAPID).

Königsrainer A, Templin S, Capobianco I, Königsrainer I, Bitzer M, Zender L, Sipos B, Kanz L, Wagner S, Nadalin S.

Ann Surg. 2018 Jun 18. doi: 10.1097/SLA.0000000000002861. [Epub ahead of print]

PMID:
29916882
14.

Mapping the HLA Ligandome of Colorectal Cancer Reveals an Imprint of Malignant Cell Transformation.

Löffler MW, Kowalewski DJ, Backert L, Bernhardt J, Adam P, Schuster H, Dengler F, Backes D, Kopp HG, Beckert S, Wagner S, Königsrainer I, Kohlbacher O, Kanz L, Königsrainer A, Rammensee HG, Stevanović S, Haen SP.

Cancer Res. 2018 Aug 15;78(16):4627-4641. doi: 10.1158/0008-5472.CAN-17-1745. Epub 2018 May 22.

15.

HLA ligandome analysis of primary chronic lymphocytic leukemia (CLL) cells under lenalidomide treatment confirms the suitability of lenalidomide for combination with T-cell-based immunotherapy.

Nelde A, Kowalewski DJ, Backert L, Schuster H, Werner JO, Klein R, Kohlbacher O, Kanz L, Salih HR, Rammensee HG, Stevanović S, Walz JS.

Oncoimmunology. 2018 Feb 14;7(4):e1316438. doi: 10.1080/2162402X.2017.1316438. eCollection 2018.

16.

Dasatinib overrides the differentiation blockage in a patient with mutant-KIT D816V positive CBFβ-MYH11 leukemia.

Kampa-Schittenhelm KM, Vogel W, Bonzheim I, Fend F, Horger M, Kanz L, Soekler M, Schittenhelm MM.

Oncotarget. 2018 Jan 31;9(14):11876-11882. doi: 10.18632/oncotarget.24376. eCollection 2018 Feb 20.

17.

[Follow-up Care in Cancer: Selected Solid Tumors and Hematological Neoplasias].

Rörden M, Hinterleitner C, Metzger J, Kanz L.

Dtsch Med Wochenschr. 2018 Mar;143(5):334-342. doi: 10.1055/s-0043-124254. Epub 2018 Mar 5. German.

PMID:
29506300
18.

Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV.

Saussele S, Hehlmann R, Fabarius A, Jeromin S, Proetel U, Rinaldetti S, Kohlbrenner K, Einsele H, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Oppliger Leibundgut E, Heim D, Krause SW, Hofmann WK, Hasford J, Pfirrmann M, Müller MC, Hochhaus A, Lauseker M.

Leukemia. 2018 May;32(5):1222-1228. doi: 10.1038/s41375-018-0055-7. Epub 2018 Feb 26.

19.

T-cell-depleted haploidentical stem cell transplantation results improve with time in adults with acute leukemia: A study from the Acute Leukemia Working Party of the European Society of Blood and Marrow Transplantation (EBMT).

Sestili S, Labopin M, Ruggeri A, Velardi A, Ciceri F, Maertens J, Kanz L, Aversa F, Lewalle P, Bunjes D, Mohty M, Nagler A.

Cancer. 2018 May 15;124(10):2142-2150. doi: 10.1002/cncr.31310. Epub 2018 Feb 22.

20.

Molecular recognition patterns of anti-topoisomerase I-antibodies in patients with systemic sclerosis before and after autologous stem cell transplantation.

Glaeser L, Henes J, Kötter I, Vogel W, Kanz L, Klein R.

Clin Exp Rheumatol. 2018 Jul-Aug;36 Suppl 113(4):28-35. Epub 2018 Feb 13.

21.

Low plasma protein Z levels are associated with an increased risk for perioperative bleedings.

Hinterleitner C, Kreisselmeier KP, Pecher AC, Mauz PS, Kanz L, Kopp HG, Jaschonek KG.

Eur J Haematol. 2018 May;100(5):403-411. doi: 10.1111/ejh.13031. Epub 2018 Mar 26.

PMID:
29360177
22.

Haploidentical transplant in patients with myelodysplastic syndrome.

Robin M, Porcher R, Ciceri F, van Lint MT, Santarone S, Ehninger G, Blaise D, Güllbas Z, Gonzáles Muñiz S, Michallet M, Velardi A, Koster L, Maertens J, Sierra J, Selleslag D, Radujkovic A, Díez-Martin JL, Kanz L, Arroyo CH, Niederwieser D, Huang H, McDonald A, de Witte T, Koc Y, Kröger N.

Blood Adv. 2017 Sep 27;1(22):1876-1883. doi: 10.1182/bloodadvances.2017007146. eCollection 2017 Oct 10.

23.

Favorable immune signature in CLL patients, defined by antigen-specific T-cell responses, might prevent second skin cancers.

Walz JS, Kowalewski DJ, Backert L, Nelde A, Kohlbacher O, Weide B, Kanz L, Salih HR, Rammensee HG, Stevanović S.

Leuk Lymphoma. 2018 Aug;59(8):1949-1958. doi: 10.1080/10428194.2017.1403022. Epub 2018 Jan 3.

PMID:
29295645
24.

Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of the European Society of Blood and Marrow Transplantation.

Schmid C, de Wreede LC, van Biezen A, Finke J, Ehninger G, Ganser A, Volin L, Niederwieser D, Beelen D, Alessandrino P, Kanz L, Schleuning M, Passweg J, Veelken H, Maertens J, Cornelissen JJ, Blaise D, Gramatzki M, Milpied N, Yakoub-Agha I, Mufti G, Rovira M, Arnold R, de Witte T, Robin M, Kröger N.

Haematologica. 2018 Feb;103(2):237-245. doi: 10.3324/haematol.2017.168716. Epub 2017 Nov 3.

25.

NFAT2 is a critical regulator of the anergic phenotype in chronic lymphocytic leukaemia.

Märklin M, Heitmann JS, Fuchs AR, Truckenmüller FM, Gutknecht M, Bugl S, Saur SJ, Lazarus J, Kohlhofer U, Quintanilla-Martinez L, Rammensee HG, Salih HR, Kopp HG, Haap M, Kirschniak A, Kanz L, Rao A, Wirths S, Müller MR.

Nat Commun. 2017 Oct 2;8(1):755. doi: 10.1038/s41467-017-00830-y.

26.

Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trial.

Einsele H, Engelhardt M, Tapprich C, Müller J, Liebisch P, Langer C, Kropff M, Mügge LO, Jung W, Wolf HH, Metzner B, Hart C, Gramatzki M, Hertenstein B, Pfreundschuh M, Rösler W, Fischer T, Maschmeyer G, Kanz L, Hess G, Jäger E, Bentz M, Dürk HA, Salwender H, Hebart H, Straka C, Knop S.

Br J Haematol. 2017 Nov;179(4):586-597. doi: 10.1111/bjh.14920. Epub 2017 Sep 29.

PMID:
28961309
27.

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.

Hehlmann R, Lauseker M, Saußele S, Pfirrmann M, Krause S, Kolb HJ, Neubauer A, Hossfeld DK, Nerl C, Gratwohl A, Baerlocher GM, Heim D, Brümmendorf TH, Fabarius A, Haferlach C, Schlegelberger B, Müller MC, Jeromin S, Proetel U, Kohlbrenner K, Voskanyan A, Rinaldetti S, Seifarth W, Spieß B, Balleisen L, Goebeler MC, Hänel M, Ho A, Dengler J, Falge C, Kanz L, Kremers S, Burchert A, Kneba M, Stegelmann F, Köhne CA, Lindemann HW, Waller CF, Pfreundschuh M, Spiekermann K, Berdel WE, Müller L, Edinger M, Mayer J, Beelen DW, Bentz M, Link H, Hertenstein B, Fuchs R, Wernli M, Schlegel F, Schlag R, de Wit M, Trümper L, Hebart H, Hahn M, Thomalla J, Scheid C, Schafhausen P, Verbeek W, Eckart MJ, Gassmann W, Pezzutto A, Schenk M, Brossart P, Geer T, Bildat S, Schäfer E, Hochhaus A, Hasford J.

Leukemia. 2017 Nov;31(11):2398-2406. doi: 10.1038/leu.2017.253. Epub 2017 Aug 14.

28.

Follow-up of patients with refractory or relapsed multiple myeloma after allogeneic hematopoietic cell transplantation.

Schneidawind C, Duerr-Stoerzer S, Faul C, Kanz L, Weisel K, Bethge W, Schneidawind D.

Clin Transplant. 2017 Jul;31(7). doi: 10.1111/ctr.12994. Epub 2017 May 26.

PMID:
28470884
29.

HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy.

Nelde A, Walz JS, Kowalewski DJ, Schuster H, Wolz OO, Peper JK, Cardona Gloria Y, Langerak AW, Muggen AF, Claus R, Bonzheim I, Fend F, Salih HR, Kanz L, Rammensee HG, Stevanović S, Weber AN.

Oncoimmunology. 2016 Dec 23;6(3):e1219825. doi: 10.1080/2162402X.2016.1219825. eCollection 2017.

30.

The hypomorphic TERT A1062T variant is associated with increased treatment-related toxicity in acute myeloid leukemia.

Both A, Krauter J, Damm F, Thol F, Göhring G, Heuser M, Ottmann O, Lübbert M, Wattad M, Kanz L, Schlimok G, Raghavachar A, Fiedler W, Kirchner H, Brugger W, Schlegelberger B, Heil G, Ganser A, Wagner K.

Ann Hematol. 2017 Jun;96(6):895-904. doi: 10.1007/s00277-017-2967-0. Epub 2017 Mar 22.

PMID:
28331964
31.

Haploidentical hematopoietic cell transplantation using in vitro T cell depleted grafts as salvage therapy in patients with disease relapse after prior allogeneic transplantation.

Haen SP, Groh C, Schumm M, Backert L, Löffler MW, Federmann B, Faul C, Dörfel D, Vogel W, Handgretinger R, Kanz L, Bethge WA.

Ann Hematol. 2017 May;96(5):817-827. doi: 10.1007/s00277-017-2941-x. Epub 2017 Feb 28.

PMID:
28247058
32.

Uric acid as a novel biomarker for bone-marrow function and incipient hematopoietic reconstitution after aplasia in patients with hematologic malignancies.

Haen SP, Eyb V, Mirza N, Naumann A, Peter A, Löffler MW, Faul C, Vogel W, Bethge WA, Rammensee HG, Kanz L, Heni M.

J Cancer Res Clin Oncol. 2017 May;143(5):759-771. doi: 10.1007/s00432-017-2348-z. Epub 2017 Feb 16.

PMID:
28210842
33.

Prominent Oncogenic Roles of EVI1 in Breast Carcinoma.

Wang H, Schaefer T, Konantz M, Braun M, Varga Z, Paczulla AM, Reich S, Jacob F, Perner S, Moch H, Fehm TN, Kanz L, Schulze-Osthoff K, Lengerke C.

Cancer Res. 2017 Apr 15;77(8):2148-2160. doi: 10.1158/0008-5472.CAN-16-0593. Epub 2017 Feb 16.

34.

A meta-analysis of HLA peptidome composition in different hematological entities: entity-specific dividing lines and "pan-leukemia" antigens.

Backert L, Kowalewski DJ, Walz S, Schuster H, Berlin C, Neidert MC, Schemionek M, Brümmendorf TH, Vucinic V, Niederwieser D, Kanz L, Salih HR, Kohlbacher O, Weisel K, Rammensee HG, Stevanovic S, Walz JS.

Oncotarget. 2017 Jul 4;8(27):43915-43924. doi: 10.18632/oncotarget.14918.

35.

Treatment of familial Mediterranean fever with anakinra in patients unresponsive to colchicine.

Pecher AC, Igney-Oertel A, Kanz L, Henes J.

Scand J Rheumatol. 2017 Sep;46(5):407-409. doi: 10.1080/03009742.2016.1245780. Epub 2017 Jan 18. No abstract available.

PMID:
28097903
36.

Thymic findings before and after autologous stem cell transplantation for severe systemic sclerosis: a retrospective study using computed tomography in the pre- and post-transplantation setting.

Henes JC, Wirths S, Vogel W, Xenitidis T, Kanz L, Horger M.

Clin Exp Rheumatol. 2017 May-Jun;35 Suppl 104(2):11-12. Epub 2017 Jan 13. No abstract available.

37.

GM-CSF treatment is not effective in congenital neutropenia patients due to its inability to activate NAMPT signaling.

Koch C, Samareh B, Morishima T, Mir P, Kanz L, Zeidler C, Skokowa J, Welte K.

Ann Hematol. 2017 Mar;96(3):345-353. doi: 10.1007/s00277-016-2894-5. Epub 2016 Dec 14.

PMID:
27966038
38.

Analysis of anti-topoisomerase I antibodies in patients with systemic sclerosis before and after autologous stem cell transplantation.

Henes J, Glaeser L, Kötter I, Vogel W, Kanz L, Klein R.

Rheumatology (Oxford). 2017 Mar 1;56(3):451-456. doi: 10.1093/rheumatology/kew319.

PMID:
27940597
39.

Sequential chemotherapy followed by reduced-intensity conditioning and allogeneic haematopoietic stem cell transplantation in adult patients with relapse or refractory acute myeloid leukaemia: a survey from the Acute Leukaemia Working Party of EBMT.

Ringdén O, Labopin M, Schmid C, Sadeghi B, Polge E, Tischer J, Ganser A, Michallet M, Kanz L, Schwerdtfeger R, Nagler A, Mohty M; Acute Leukaemia Working Party of the EBMT.

Br J Haematol. 2017 Feb;176(3):431-439. doi: 10.1111/bjh.14428. Epub 2016 Nov 23.

PMID:
27879990
40.

Graft versus self (GvS) against T-cell autoantigens is a mechanism of graft-host interaction.

Mirza N, Zierhut M, Korn A, Bornemann A, Vogel W, Schmid-Horch B, Bethge WA, Stevanović S, Salih HR, Kanz L, Rammensee HG, Haen SP.

Proc Natl Acad Sci U S A. 2016 Nov 29;113(48):13827-13832. Epub 2016 Nov 10.

41.

Evi1 regulates Notch activation to induce zebrafish hematopoietic stem cell emergence.

Konantz M, Alghisi E, Müller JS, Lenard A, Esain V, Carroll KJ, Kanz L, North TE, Lengerke C.

EMBO J. 2016 Nov 2;35(21):2315-2331. Epub 2016 Sep 16.

42.

Safety and efficacy of thiotepa-based conditioning for allogeneic transplantation in AML: a survey from the ALWP of the EBMT.

Eder S, Labopin M, Finke J, Bunjes D, Olivieri A, Santarone S, Rambaldi A, Kanz L, Messina G, Mohty M, Nagler A.

Bone Marrow Transplant. 2017 Feb;52(2):238-244. doi: 10.1038/bmt.2016.239. Epub 2016 Sep 19.

PMID:
27643865
43.

Anti-thymocyte globulin-induced hyperbilirubinemia in patients with myelofibrosis undergoing allogeneic hematopoietic cell transplantation.

Ecsedi M, Schmohl J, Zeiser R, Drexler B, Halter J, Medinger M, Duyster J, Kanz L, Passweg J, Finke J, Bethge W, Lengerke C.

Ann Hematol. 2016 Oct;95(10):1627-36. doi: 10.1007/s00277-016-2758-z. Epub 2016 Aug 2.

PMID:
27480090
44.

Long-term survival correlates with immunological responses in renal cell carcinoma patients treated with mRNA-based immunotherapy.

Rittig SM, Haentschel M, Weimer KJ, Heine A, Müller MR, Brugger W, Horger MS, Maksimovic O, Stenzl A, Hoerr I, Rammensee HG, Holderried TA, Kanz L, Pascolo S, Brossart P.

Oncoimmunology. 2015 Oct 29;5(5):e1108511. doi: 10.1080/2162402X.2015.1108511. eCollection 2016 May.

45.

Allogeneic hematopoietic cell transplantation in patients ⩾70 years: which patients may benefit?

Haen SP, Pham M, Faul C, Dörfel D, Vogel W, Kanz L, Bethge WA.

Blood Cancer J. 2016 Jul 8;6(7):e443. doi: 10.1038/bcj.2016.54. No abstract available.

46.

Expression of 4-1BB and its ligand on blasts correlates with prognosis of patients with AML.

Schmohl JU, Nuebling T, Wild J, Kroell T, Kanz L, Salih HR, Schmetzer H.

J Investig Med. 2016 Dec;64(8):1252-1260. Epub 2016 Jul 7.

PMID:
27388616
47.

Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network.

Hermine O, Hoster E, Walewski J, Bosly A, Stilgenbauer S, Thieblemont C, Szymczyk M, Bouabdallah R, Kneba M, Hallek M, Salles G, Feugier P, Ribrag V, Birkmann J, Forstpointner R, Haioun C, Hänel M, Casasnovas RO, Finke J, Peter N, Bouabdallah K, Sebban C, Fischer T, Dührsen U, Metzner B, Maschmeyer G, Kanz L, Schmidt C, Delarue R, Brousse N, Klapper W, Macintyre E, Delfau-Larue MH, Pott C, Hiddemann W, Unterhalt M, Dreyling M; European Mantle Cell Lymphoma Network.

Lancet. 2016 Aug 6;388(10044):565-75. doi: 10.1016/S0140-6736(16)00739-X. Epub 2016 Jun 14.

PMID:
27313086
48.

[Hematologic chest pain].

Haen SP, Mannal R, Steeg M, Seizer P, Rockenstiehl M, Mackensen-Haen S, Horger M, Kanz L, Vogel W.

Dtsch Med Wochenschr. 2016 Apr;141(9):634. doi: 10.1055/s-0041-109909. Epub 2016 Apr 28. German.

PMID:
27123729
49.

Cardiac Myeloid Sarcoma: Multimodality Radiologic Imaging Features and Pathologic Correlation.

Dörfel D, Häntschel M, Federmann B, Haen S, Fend F, Müller II, Salih HR, Vogel W, Kanz L, Horger M.

Am J Med. 2016 Aug;129(8):e117-20. doi: 10.1016/j.amjmed.2016.03.028. Epub 2016 Apr 18. No abstract available.

PMID:
27103046
50.

Expression of RANK-L and in part of PD-1 on blasts in patients with acute myeloid leukemia correlates with prognosis.

Schmohl JU, Nuebling T, Wild J, Kroell T, Kanz L, Salih HR, Schmetzer H.

Eur J Haematol. 2016 Dec;97(6):517-527. doi: 10.1111/ejh.12762. Epub 2016 Jun 5.

PMID:
27096305

Supplemental Content

Support Center